Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,137,492.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $41,076.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Trading Up 0.5 %

UTHR stock opened at $318.55 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $321.80. The business has a 50 day simple moving average of $274.77 and a two-hundred day simple moving average of $244.09. The company has a market capitalization of $14.13 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 4.77 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.86 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Rise Advisors LLC purchased a new stake in shares of United Therapeutics in the first quarter worth about $32,000. GAMMA Investing LLC bought a new stake in United Therapeutics in the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares in the last quarter. Janiczek Wealth Management LLC boosted its position in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on UTHR shares. Oppenheimer boosted their target price on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. raised their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Finally, Wells Fargo & Company increased their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, June 12th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.